Stockscreener 앱 받기
16.88
1.02%
0.17
시간 외 거래:
16.88
Bausch Lomb Corp 주식(BLCO)의 최신 뉴스
Bausch & Lomb Legal Chief Sees Pay Dip To $3.6M In 2025 - Law360
Form 8-KCurrent report - ADVFN
Bausch + Lomb Corp. Opens with a 5.46% Gain, Outperforming S&P 500 - Markets Mojo
BLCO SEC FilingsBausch + Lomb Corporation 10-K, 10-Q, 8-K Forms - Stock Titan
[ARS] Bausch & Lomb Corp SEC Filing - Stock Titan
Bausch + Lomb (NYSE: BLCO) seeks approval to expand equity plan and elect board - Stock Titan
Bausch + Lomb Corporation - Baystreet.ca
Bausch + Lomb Corporation Receives FDA 510(k) Clearance For Bi-Blade+ Dual-Port Vitrectomy Cutter And Adaptive Fluidics Advanced Update - marketscreener.com
Bausch + Lomb Corp stock: Eye health innovation drives undervaluation debate - AD HOC NEWS
Bausch + Lomb receives FDA clearance for surgical device - Investing.com
Bausch + Lomb Receives FDA 510(k) Clearance for Bi-Blade+™ Dual-Port Vitrectomy Cutter and Adaptive Fluidics™ Advanced Update - Business Wire
Bausch Lomb (NYSE:BLCO) Eye Health Story Gains Attention On Nyse Composite Today - Kalkine Media
Stifel Maintains Bausch + Lomb Corp.(BLCO.US) With Hold Rating, Raises Target Price to $16.34 - 富途牛牛
Stocks in play: Bausch + Lomb Corporation - Yahoo! Finance Canada
A Look At Bausch + Lomb (NYSE:BLCO) Valuation As ASCRS Presentations Highlight Eye Health Portfolio - simplywall.st
Citi Maintains Bausch + Lomb Corp.(BLCO.US) With Buy Rating, Maintains Target Price $21 - 富途牛牛
Bausch + Lomb Launches Preloaded enVista Envy™ Full Range of Vision Intraocular Lenses in Europe - Business Wire
BLCO: Evercore ISI Group Adjusts Price Target While Maintaining Rating | BLCO Stock News - GuruFocus
Evercore Maintains Bausch + Lomb Corp.(BLCO.US) With Hold Rating, Cuts Target Price to $17 - 富途牛牛
Bausch + Lomb Corporation (BLCO) stock price, news, quote and history - Yahoo Finance Singapore
Dry eye and cataract data lead Bausch + Lomb's 45-study ASCRS lineup - Stock Titan
Q4 Rundown: Bausch + Lomb (NYSE:BLCO) Vs Other Medical Devices & SuppliesSpecialty Stocks - Yahoo! Finance Canada
BLCO Stock Price, Quote & Chart | BAUSCH + LOMB CORP (NYSE:BLCO) - ChartMill
Bausch + Lomb Corporation (NYSE:BLCO) Receives Average Rating of "Hold" from Analysts - MarketBeat
Should Positive ELIOS Glaucoma Trial Results Require Action From Bausch + Lomb (BLCO) Investors? - simplywall.st
Bausch + Lomb Will Release First-Quarter 2026 Financial Results on April 29 - Yahoo Finance
Bausch + Lomb Corp Stock: Eye Health Leader with Strong Product Portfolio and Growth Potential for I - AD HOC NEWS
Tudor Investment Corp ET AL Takes $2.25 Million Position in Bausch + Lomb Corporation $BLCO - MarketBeat
Bausch + Lomb Corp. Experiences Revision in Stock Evaluation Amid Mixed Technical Indicators - Markets Mojo
A Look At Bausch + Lomb (BLCO) Valuation After Recent Share Price Pullback - Yahoo Finance
Bausch And Lomb (NYSE:BLCO) Shares Draw Eyes Across Nyse Composite Today - Kalkine Media
3 Reasons BLCO is Risky and 1 Stock to Buy Instead - Yahoo Finance
A Bausch + Lomb Director Just Bought $77,000 in Stock. That's Only Half the Story - Yahoo Finance
A Bausch + Lomb Director Just Bought $77,000 in Stock. That's Only Half the Story - The Motley Fool
Goldman Sachs Maintains Bausch + Lomb Corp.(BLCO.US) With Hold Rating, Maintains Target Price $19 - 富途牛牛
Bausch + Lomb Achieves Key Milestone in Glaucoma Treatment with ELIOS System - Intellectia AI
Bausch + Lomb Announces Positive 24-Month U.S. Data on the ELIOS™ System for Treatment of Glaucoma - BioSpace
Bausch + Lomb reports positive glaucoma trial results for ELIOS - Investing.com
Glaucoma laser left 82% of patients medication-free in U.S. trial - Stock Titan
Bausch + Lomb Corp Stock (ISIN: CA07174N1090) Faces Headwinds Amid Vision Care Market Shifts and Deb - AD HOC NEWS
RBC reiterates Bausch & Lomb stock rating on DED rival delay - Investing.com Australia
Bausch + Lomb Corp. Experiences Revision in Stock Evaluation Amid Mixed Market Signals - Markets Mojo
RBC reiterates Bausch & Lomb stock rating on DED rival delay By Investing.com - Investing.com South Africa
Bausch + Lomb Corp Stock (ISIN: CA07174N1090) Faces Headwinds Amid Vision Care Demand Slowdown and D - AD HOC NEWS
Eye Care Giant Posts $5.1 Billion in Revenue as One Investor Builds Major Position - AOL.com
Bausch + Lomb Corporation (NYSE:BLCO) Sees Large Decline in Short Interest - MarketBeat
Bausch + Lomb Corp Stock (ISIN: CA07174N1090) Faces Headwinds Amid Vision Care Demand Shifts - AD HOC NEWS
Is It Time To Reconsider Bausch + Lomb (BLCO) After Recent Share Price Weakness - Yahoo Finance
Bausch + Lomb Corporation $BLCO Shares Purchased by Compass Rose Asset Management LP - MarketBeat
Bausch + Lomb Corporation Investigated by the Portnoy Law Firm - GlobeNewswire
0.06%
1.84%
자본화:
|
볼륨(24시간):